Objectives: The b-lactamase inhibitor relebactam can restore imipenem activity against imipenem nonsusceptible pathogens.
Introduction
Infections caused by multidrug-resistant Gram-negative pathogens, ESBL-producing Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter spp., are difficult to treat and associated with high mortality. [1] [2] [3] Carbapenems fulfil a critical role in the treatment of serious bacterial infections due to these pathogens, both as empirical therapy in settings with high background levels of antibiotic resistance and as definitive therapy for confirmed MDR strains. [4] [5] [6] [7] [8] The increasing prevalence of carbapenem-resistant bacterial pathogens is therefore a major global health threat, with the US CDC considering carbapenemresistant Enterobacteriaceae, one of only three bacterial threats at the highest hazard level. 3, [9] [10] [11] The most common carbapenem resistance mechanism is the production of carbapenemases, which are b-lactamase enzymes able to hydrolyse carbapenem-class antibacterials. 12 Resistance can also be mediated by other Relebactam in combination with imipenem/cilastatin is thus currently under clinical development for treating Gramnegative infections. Phase 1 studies demonstrated that single and multiple intravenous (iv) doses of relebactam, ranging from 50 to 625 mg, co-administered with imipenem/cilastatin every 6 h (q6h) were generally safe and well-tolerated. Relebactam doses for subsequent clinical trials were selected based on robust preclinical pharmacokinetic/pharmacodynamic (PK/PD) studies, translational PK/PD modelling and clinical PK data. Overall, these data suggested that relebactam 125 mg q6h would meet the established PK/PD target measure, but that 250 mg q6h might be necessary to achieve plasma exposures sufficient to cover highly resistant pathogens. 22 MDR pathogens are increasing as a cause of complicated urinary tract infections (cUTI), requiring empirical carbapenem use in some locations to overcome these high levels of resistance. 7, 8, [23] [24] [25] [26] [27] [28] [29] We therefore sought to evaluate the combination of imipenem/cilastatin and relebactam for the treatment of cUTI. To this end, we prospectively conducted a randomized, controlled Phase 2 trial comparing efficacy, safety and tolerability of two doses of relebactam (250 and 125 mg) plus imipenem/cilastatin versus imipenem/ cilastatin plus placebo in adult patients with cUTI, not limited to infections involving multidrug-resistant pathogens. The trial was designed to test the hypothesis that imipenem/cilastatin plus relebactam is non-inferior to imipenem/cilastatin alone for the treatment of cUTI.
Patients and methods
MK-7655A Protocol 003 was a prospective, randomized, double-blind, multicentre, non-inferiority (with nested superiority) Phase 2b dose-ranging study. The trial enrolled adult patients with cUTI or acute pyelonephritis (regardless of antibacterial susceptibility of causative pathogens) at 34 secondary and tertiary hospitals in 11 countries (Table S1 , available as Supplementary data at JAC Online) from December 2012 to July 2015.
Ethics
The study was conducted in accordance with principles of Good Clinical Practice and was approved by the appropriate institutional review boards and regulatory agencies (NCT01505634).
Patient population, randomization and study design
Eligible patients were !18 years old with either clinically suspected and/or bacteriologically documented cUTI or acute pyelonephritis, requiring hospitalization and iv antibacterial therapy. Patients also had to have pyuria and to have their infection confirmed by urine culture within 48 h of enrolment; patients could be enrolled prior to culture results if clinical findings supported the diagnosis. Patients were ineligible if they received antibacterial therapy effective against the identified causative pathogen(s) after culture collection and prior to study therapy initiation. Patients who received .24 h of systemic antibacterials effective against presumed/documented causative pathogen(s) within 72 h prior to study entry were also excluded. Final inclusion and exclusion criteria are listed in Table 1 (including full diagnostic  criteria for cUTI and pyelonephritis) .
Patients were screened within 24 h prior to study entry. Eligible patients were randomized (blocked randomization) via a centralized, interactive voice system in a 1:1:1 ratio to one of three treatment groups, with $100 patients per group: relebactam 250 mg, relebactam 125 mg or placebo, each together with imipenem/cilastatin 500 mg (Figure 1) . Relebactam (or placebo) and imipenem/cilastatin were concurrently administered as 30 min iv infusions q6h (via two separate infusion bags containing 150 mL 0.9% normal saline, through a single cannula). The dose regimen for imipenem/cilastatin was adjusted in patients with renal insufficiency and/or low body weight according to the approved imipenem/cilastatin label 30 ; in these instances, the total relebactam dose was adjusted proportionally to the imipenem/cilastatin dose and given at the same infusion frequency. At each study site, an unblinded pharmacist (without involvement in any efficacy or safety evaluations) prepared the study treatment. Patients, investigators and all other study personnel remained blinded to treatment. Patients with adequate therapeutic response could be switched to openlabel oral ciprofloxacin after 96 h of iv study therapy. Total duration of study therapy (either iv alone or iv plus subsequent oral ciprofloxacin) could not exceed 14 days.
Assessments
Potential participants were screened within 24 h prior to study entry. Patients were evaluated for efficacy at three different visits: (i) discontinuation of iv therapy (DCIV), which could have been at any time from Day 5 to Day 14; (ii) early follow-up (EFU), 5-9 days after completion of all study therapy (either iv or iv plus oral, if applicable); and (iii) late follow-up (LFU), 28-42 days after completion of all study therapy. While on iv therapy, patients were evaluated daily for safety and tolerability (Table S2) .
Microbiological response was determined based on the results of urine cultures collected at each efficacy assessment relative to the pathogen(s) isolated at baseline/admission and was classified as favourable or unfavourable (Table S3) . Clinical response, also classified as favourable or unfavourable, was determined by comparing cUTI signs/symptoms with those at baseline (Table S3) .
Endpoints
The primary efficacy endpoint was the proportion of patients with a favourable microbiological response at DCIV in the microbiologically evaluable (ME) population. The ME population excluded patients with protocol deviations that could substantially affect results of the primary efficacy endpoint (i.e. not meeting protocol definitions of cUTI/acute pyelonephritis; prestudy urine culture failing to grow !1 Gram-negative and/or anaerobic pathogen at sufficient quantity; inclusion/exclusion violations impacting efficacy assessment; receiving ,96 h of iv study therapy). The microbiological ITT (MITT) population, defined as patients who received !1 dose of iv study therapy and had a prestudy urine culture growing !1 Gram-negative and/or anaerobic pathogen at any quantity, was used for a sensitivity analysis of the primary endpoint. Secondary efficacy endpoints, all assessed in the ME population, were: (i) microbiological responses at EFU and LFU; (ii) microbiological response at DCIV in patients with imipenem-resistant pathogens; and (iii) clinical response at DCIV, EFU and LFU. Composite clinical and microbiological response at EFU was a pre-specified exploratory endpoint. Microbiological response was selected as the primary endpoint, as per regulatory guidance at the time of study initiation, 31 and because Imipenem/cilastatin plus relebactam in cUTI b Maximum treatment duration of iv study treatment and oral ciprofloxacin, if applicable, combined was 14 days. c 'All antibacterial therapy' comprised iv study treatment and oral ciprofloxacin, if applicable. IMI, imipenem/cilastatin. continued bacteriuria strongly predisposes patients to cUTI relapse. The ME population was the most appropriate analysis set to evaluate the potential effect of relebactam dose-ranging, in line with similar previous studies in this setting and with regulatory guidance. 32 DCIV was considered the optimal visit to assess microbiological efficacy, to focus on the effect of iv study therapy only (rather than the combined effects of iv and oral step-down).
JAC
All adverse events (AEs) occurring from first dose of iv study therapy through 14 days following study completion were collected and reported. The all-patients-as-treated population, i.e. patients who received !1 dose of study drug, was used to assess safety and tolerability based on AE reporting and laboratory test results. Given transient increases in liver transaminases observed in a small number of subjects receiving multiple relebactam doses in Phase 1 studies, our trial carefully evaluated the potential risk for drug-induced liver injury. For this purpose, two safety events of clinical interest (ECI) were pre-specified. ECI no. 1: AST or ALT !5% upper limit of normal (ULN); and ECI no. 2: AST or ALT !3% ULN, accompanied by total bilirubin !2% ULN and alkaline phosphatase ,2% ULN.
Statistical analysis
For the primary efficacy endpoint, 95% CIs and P values (one-sided a " 0.025) for between-treatment differences (imipenem/cilastatin!relebactam minus control) were calculated using Miettinen and Nurminen's method. To conclude non-inferiority of imipenem/cilastatin!relebactam to imipenem/cilastatin alone, the lower bound of these 95% CIs had to be above -15%. A fixed testing sequence was employed to account for multiplicity, starting with imipenem/cilastatin!relebactam 250 mg versus imipenem/cilastatin!placebo, followed by imipenem/cilastatin!relebactam 125 mg versus imipenem/cilastatin!placebo. If either relebactam dose was found non-inferior to control, superiority of that dose versus control was to be tested. Statistical analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC, USA).
Only the primary endpoint was powered for formal statistical comparison. Randomizing $100 patients into each treatment group, the study had 87% power to demonstrate non-inferiority of the imipenem/cilastatin!relebactam groups to control, assuming: the underlying treatment difference was 0%; a non-inferiority margin of -15%; a 95% microbiological response rate for the control group; and a 60% microbiological evaluability rate.
Results

Patients
The trial ended after the protocol-specified number of patients was enrolled. No patients were prematurely unblinded. Of the 302 patients randomized, 298 were treated and 230 (77.2%) were ME at DCIV ( Imipenem/cilastatin plus relebactam in cUTI JAC 250 mg, 79 in the imipenem/cilastatin!relebactam 125 mg and 80 in the imipenem/cilastatin!placebo group. Over 90% of patients were enrolled in Europe (Table S1 ). Reasons for nonevaluability, mostly the baseline culture not meeting protocolspecified requirements, are provided in Table S4 . Non-study antibacterial use in the ME population was low during the pre-study period (7.8%) and the study (7.4%) ( (Table S6 ). Time to discontinuation of iv therapy is shown in Figure S1 .
In the ME at DCIV population, treatment groups were generally well balanced for baseline characteristics ( Table 2 ). The most common baseline pathogens were Escherichia coli and Klebsiella pneumoniae. Overall, 131 of 275 isolates (47.6%) were non-susceptible to ciprofloxacin, 89 of 261 (34.1%) nonsusceptible to at least one third-generation cephalosporin, and 138 of 275 (50.2%) were multidrug-resistant (i.e. nonsusceptible to !1 agent from !3 antibacterial classes). At baseline, 25 of 220 patients (11.4%) with confirmed Gram-negative Sims et al.
pathogens had a pathogen non-susceptible to imipenem ( Table 3 ). Fifteen of these had baseline pathogens also not susceptible to imipenem!relebactam: Proteus mirabilis (n " 5), Acinetobacter baumannii (n " 4), Morganella morganii (n " 4), Providencia rettgeri (n " 1) and P. aeruginosa (n " 1). The positive effect of relebactam on restoring in vitro imipenem activity was most noticeable with M. morganii and P. aeruginosa isolates.
Baseline characteristics in the all-randomized and MITT populations were similar to those in the ME at DCIV population (data not shown).
Efficacy
At DCIV, .95% of ME patients in each treatment arm had favourable microbiological responses: 95.5% with imipenem/cilastatin!relebactam 250 mg, 98.6% with imipenem/cilastatin! relebactam 125 mg and 98.7% with imipenem/cilastatin!placebo ( Figure 3 ). Both the 250 mg and the 125 mg dose of relebactam combined with imipenem/cilastatin were non-inferior to imipenem/cilastatin!placebo. All patients with unfavourable microbiological response had imipenem-susceptible pathogens at baseline. Of patients with imipenem-non-susceptible baseline pathogens, 23 were ME and all of these achieved favourable microbiological response at DCIV (10 of 10 with imipenem/cilastatin!relebactam 250 mg, seven of seven with imipenem/cilastatin!relebactam 125 mg and six of six with imipenem/ cilastatin!placebo). Overall, microbiological outcomes were also similar between treatment arms in important sub-populations, some of which had only small patient numbers and thus very wide 95% CIs (Figure 4 ). Among patients with concurrent bacteraemia for whom a microbiological response was available, three of four receiving imipenem/cilastatin!relebactam 250 mg, six of six receiving imipenem/cilastatin!relebactam 125 mg and three of three receiving imipenem/cilastatin!placebo had favourable outcomes. Decreases in microbiological responses after DCIV were observed, with similar reductions across all three treatment groups at the EFU and LFU visits ( Figure 3 , Table 4 ). Results in ME patients were generally consistent with those in the sensitivity analysis done in the MITT population ( Figure 3 , Table S7 ). At the DCIV visit, favourable clinical response rates in ME patients were generally similar across treatment groups (Table 4) . Only one ME patient (in the 250 mg group) was determined to have an unfavourable response at DCIV; this patient had an imipenem-susceptible baseline pathogen and a favourable microbiological response. A slight decrease in clinical response rates Figure 3 . Favourable response at discontinuation of iv therapy in the ME population (primary efficacy endpoint). IMI, imipenem/cilastatin; DCIV, discontinuation of iv therapy; ME, microbiologically evaluable; MITT, microbiological intention-to-treat.
Imipenem/cilastatin plus relebactam in cUTI JAC after DCIV was observed, with generally similar reductions seen across treatment groups at EFU and LFU. Composite clinical and microbiological response rates at EFU were also similar across treatment groups (Table 4) .
Safety
Incidence, types and severity of treatment-emergent AEs were similar across all three treatment arms (Table 5) . Among the 298 patients treated, 28.3% in the imipenem/cilastatin!relebactam 250 mg, 29.3% in the imipenem/cilastatin!relebactam 125 mg and 30.0% in the imipenem/cilastatin!placebo group experienced !1 AE while receiving and/or within 14 days of the end of study therapy (Table 5) ; none were fatal. Serious treatment-emergent AEs were reported in 3.0%, 1.0% and 3.0%, respectively. Most commonly reported AEs were nausea, headache and diarrhoea (Table  5) , which were also the most frequent treatment-related AEs. Only four patients had treatment-related AEs leading to discontinuation of iv study drug: 2 of 99 (2.0%) with imipenem/cilastatin!relebactam 250 mg (diarrhoea in one patient, rash in another patient), 1 of 99 (1.0%) with imipenem/cilastatin!relebactam 125 mg (nausea) and 1 of 100 (1%) with imipenem/cilastatin ! placebo (diarrhoea). One patient each in the 250 and 125 mg groups experienced ECI no. 1, i.e. AST !5% ULN in the 250 mg (considered drug related by the investigator) and AST !5% ULN in the 125 mg group (not considered drug related). None experienced ECI no. 2.
Discussion
This randomized, controlled trial studied cUTI requiring parenteral antibacterial therapy and broadly permitted enrolment of patients with a range of cUTI types and common causative pathogens, not limited to MDR strains. The enrolled study population was representative of a wide variety of patients typically seen with cUTI. Results demonstrated the non-inferiority of two doses (250 and 125 mg) of relebactam plus imipenem/cilastatin to imipenem/cilastatin alone for treatment of cUTI in adults. At DCIV, both microbiological and clinical response rates exceeded 95% in ME patients of all three treatment groups. Microbiological response at DCIV in the ME population, the primary endpoint, was similar across arms and confirmed the non-inferiority of imipenem/cilastatin!relebactam to imipenem/cilastatin alone; the sensitivity analysis using the MITT Sims et al. Imipenem/cilastatin plus relebactam in cUTI JAC population yielded the same results, illustrating the robustness of the primary analysis. With both relebactam regimens, the incidence of safety events of interest (i.e. clinically significant liver transaminase elevations) and of AEs was low and comparable to imipenem/cilastatin alone, including AEs that were drug-related, serious or led to study drug discontinuation. The non-restrictive eligibility criteria of this study (i.e. permitting enrolment of patients with imipenem-susceptible pathogens) probably contributed to the observed lack of superiority of imipenem/cilastatin!relebactam over imipenem/cilastatin alone, especially when also considering the high clinical efficacy of imipenem/cilastatin monotherapy in treating UTI, [33] [34] [35] imipenem/cilastatin's potent activity even against MDR organisms 23, 24, 26 and the low proportion of imipenem non-susceptible pathogens ($10%) observed in our study population. Furthermore, addition of relebactam did not restore in vitro susceptibility to imipenem for about half of those imipenem-non-susceptible isolates, presumably because resistance in these pathogens was not mediated by b-lactamases vulnerable to relebactam inhibition. It was also not unexpected to see favourable treatment outcomes with imipenem/cilastatin alone in patients with imipenem-resistant pathogens. About 70% of the imipenem dose is renally excreted as unchanged drug; 36, 37 this results in very high imipenem urine concentrations (.10 lg/mL for the duration of each dosing interval), 30 which were likely sufficient to eradicate uropathogens with imipenem MICs above the CLSI susceptibility breakpoint. Notably, we observed a decrease in microbiological, and to a lesser extent clinical, response rates after the DCIV visit, reflecting the complexity of patients predisposed to cUTI; although antibacterials can resolve the cUTI episode, underlying anatomic/functional abnormalities continue to predispose these patients to recurrent infection. At EFU and LFU, clinical response rates were higher than microbiological response rates, likely because asymptomatic bacteriuria is commonly encountered in patients with abnormal urinary tracts. 38 Similar decreases in response rates from the end of iv therapy to later evaluations were also reported in a recent large Phase 3 trial comparing a cephalosporin/BLI combination with a carbapenem in cUTI. 39 The decrease in microbiological response after DCIV also directly contributed to lower composite clinical plus microbiological response rates seen at EFU.
Our results are also consistent with a recent Phase 2 study comparing imipenem/cilastatin!relebactam 250 or 125 mg to imipenem/cilastatin alone for treatment of complicated intraabdominal infection (cIAI) in adults. 22 The primary endpoint in that cIAI study was clinical response at DCIV, and success rates were high in patients who received relebactam 250 mg (96%) and relebactam 125 mg (99%); both doses demonstrated non-inferiority to imipenem/cilastatin alone (95%). A body of previous work suggests that relebactam 125 mg q6h is expected to achieve the established plasma exposure target (relebactam AUC 0-24 h of 50.1 mgÁh/L), but that greater plasma levels may be needed to treat highly resistant bacterial strains. 22 PK/PD simulations confirmed that a fixed-dose combination of imipenem/cilastatin 500 mg with relebactam 250 mg, adjusted in patients with renal impairment and/or low body weight, would achieve exposures of both imipenem/cilastatin and relebactam to cover .90% of carbapenem-resistant pathogens. 22 Of note, in our trial and in the cIAI study, both doses of relebactam in combination with imipenem/cilastatin were generally well tolerated, with a similar AE profile to imipenem/cilastatin alone. 22 Our study has certain limitations. First, the b-lactam backbone (i.e. imipenem) was the same across treatment arms, which complicates assessment of the true efficacy effect of relebactam added to imipenem/cilastatin; imipenem/cilastatin was chosen because it is an established agent for treating cUTI caused by confirmed/suspected MDR pathogens. 7, 8, 29 The relatively high number of patients that were enrolled in our trial led to a broadly representative study population, including a wide range of cUTI patient types, clinical characteristics, predisposing factors and baseline pathogens, resulting in robust conclusions. However, not restricting our study to patients with MDR causative pathogens only is also a limitation, since this is the population in which the combination of imipenem/cilastatin with relebactam potentially has the greatest clinical value. In accordance with principles of antimicrobial stewardship, use of imipenem/cilastatin combined with relebactam as an agent of last resort should be focused on settings where carbapenem-resistant pathogens may be encountered or in infections in which such pathogens have been confirmed. The rationale for selecting a broader study population was 2-fold, i.e. (i) to conduct a proof-of-concept study, following the established pathway for antibacterial drug development, and (ii) to enable a straightforward safety evaluation versus imipenem/cilastatin alone. Clinical evaluation of fixed-dose combination imipenem/ cilastatin!relebactam for infections caused by carbapenemresistant pathogens is currently underway in a Phase 3 trial (MK-7655A PN013; NCT02452047) and will provide data specific to this patient population with high unmet medical need.
In conclusion, imipenem/cilastatin!relebactam was as effective as imipenem/cilastatin alone in the treatment of cUTI in adults. A high proportion of patients in all three treatment groups, including patients with MDR strains, had favourable clinical and microbiological responses. Both doses of relebactam were well tolerated, and imipenem/cilastatin!relebactam had the same safety profile as imipenem/cilastatin alone. Since the safety profiles of relebactam at 250 and 125 mg were also comparable, and considering that 250 mg q6h is more likely to cover even highly resistant pathogens, 22 our results support the further clinical evaluation of relebactam at the 250 mg dose. 
Transparency declarations
